Sitagliptin Vildagliptin And Saxagliptin Dipeptidyl Peptidase

close
PDF
DOC
PPT
Stellungnahme der Deutschen Diabetes Gesellschaft (DDG) zu ...

Stellungnahme der Deutschen Diabetes Gesellschaft (DDG) zu ...

kritische und fachübergreifende Stellungnahme zusammen mit der Deutschen Gesellschaft für Innere Medizin (DGIM), der Deutschen Gesellschaft für Kardiologie (DGK ...
Tue, 16 Sep 2014 11:47:00 GMT
Comparison of efficacy between incretin-based therapies ...

Comparison of efficacy between incretin-based therapies ...

comparative trials analyzing efficacy, tolerability and safety profiles between the agents from these two classes. Physiology of incretins The classic ‘incretin ...
Tue, 16 Sep 2014 05:28:00 GMT
Launch Excellence in the Diabetes Market - IMS Health

Launch Excellence in the Diabetes Market - IMS Health

IMS HEALTH |LAUNCH EXCELLENCE IN THE DIABETES MARKET 5 WHITE PAPER |DIABETES LAUNCH EXCELLENCE The competitive success of ...
Wed, 17 Sep 2014 13:19:00 GMT
Australian Public Assessment Report for Linagliptin

Australian Public Assessment Report for Linagliptin

Australian Public Assessment Report for Linagliptin Proprietary Product Name: Trajenta Sponsor: Boehringer Ingleheim (Australia) Pty Ltd December 2011
Tue, 16 Sep 2014 16:48:00 GMT
CHMP ASSESSMENT REPORT FOR Onglyza - European Medicines Agency

CHMP ASSESSMENT REPORT FOR Onglyza - European Medicines Agency

Page 5 of 57 2 SCIENTIFIC DISCUSSION 2.1 Introduction Type 2 Diabetes Mellitus (T2DM) is a common chronic metabolic disorder, which can lead to
Wed, 17 Sep 2014 01:30:00 GMT
Linagliptin: new DPP-4 inhibitor for type 2 diabetes mellitus

Linagliptin: new DPP-4 inhibitor for type 2 diabetes mellitus

Type 2 diabetes mellitus (T2DM) is a chronic disorder charac - terised by progressive decline in beta cell function and insulin resist-ance leading to deterioration ...
Mon, 15 Sep 2014 18:08:00 GMT
Jentadueto, INN-linagliptin/metformin HCl

Jentadueto, INN-linagliptin/metformin HCl

Jentadueto CHMP assessment report Page 7/134. abnormalities involving insulin resistance, impaired insulin secretion, and increased glucose production.
Wed, 17 Sep 2014 11:10:00 GMT
National Medicines VOLUME 17 Information Centre 2011

National Medicines VOLUME 17 Information Centre 2011

References for type 2 Diabetes Mellitus Vol 17 No 6 2011 1. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of
Thu, 18 Sep 2014 07:27:00 GMT
第一百零二期 中華民國一百零一年十二月 ...

第一百零二期 中華民國一百零一年十二月 ...

慈濟藥訊(102)-5/16 =臨床藥學科整理= 2.1.1.6 Clopidogrel ( 如Plavix ):( 90/1/1、93/4/1、94/8/1、96/10/1、100/7/1 ...
Wed, 17 Sep 2014 12:14:00 GMT
Center For Drug Evaluation 全民健康保險藥事小組 ...

Center For Drug Evaluation 全民健康保險藥事小組 ...

財團法人醫藥品查驗中心 Center For Drug Evaluation 全民健康保險藥事小組會議. 參考資料. 糖健平膜衣錠 (Trajenta 5mg Film Coated Tablets)
Wed, 17 Sep 2014 20:14:00 GMT